Therapeutic Drug Monitoring of Maintenance Infliximab Is Beneficial for Patients with Immunemediated Inflammatory Diseases

Associate Editor Jessica R. Allegretti, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial” by Syversen et al, published in JAMA [2021; 326(23):2375-2384]. https://pubmed.ncbi.nlm.nih.gov/34932077/